Recurrent oedema of the uvula in a patient with chronic spontaneous urticaria successfully treated with omalizumab

被引:1
|
作者
Pannofino, Alessandro [1 ]
机构
[1] Policoro Hosp, Operat Unit Med, Allergol & Immunol Clin, Via Salerno, I-75025 Policoro, Matera, Italy
关键词
Uvula oedema; chronic spontaneous urticaria; CSU; omalizumab; ANGIOEDEMA; DIAGNOSIS;
D O I
10.1080/09546634.2018.1550247
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Uvula oedema is a condition characterized by a sensation of a foreign body in the oropharynx and difficulty to speak; sometimes, if associated with glottis oedema, difficulty to breathe and dysphonia are also present. Urticaria is a disease characterized by itching wheals on the skin, and sometimes angioedema. Chronic urticaria is spontaneous when the etiology is unknown. Chronic urticaria may be disabling and difficult to treat, with a negative impact on the patient's quality of life. Omalizumab administration is suggested for refractory patients as add-on therapy to the antihistamines, in a third line. In Italy, omalizumab may be used for the treatment of spontaneous chronic urticaria in patients older than 12 years, refractory to antihistamines, with UAS >3 and UAS7 > 16. We describe a case of a 62-year-old woman had had recurring uvula oedema and chronic urticaria, not responder to antihistamines and oral corticosteroids. After 6 months of treatment with omalizumab and antihistamines, no urticaria recurrence was reported and no new episodes of angioedema had occurred. Our experience showed that omalizumab might be effective in patients with recurrent uvula oedema associated with urticaria.
引用
收藏
页码:8 / 9
页数:2
相关论文
共 50 条
  • [21] Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria
    Ji, Ping
    Chen, Hao
    Yang, Yaqi
    Yang, Lin
    Wang, Yin
    Liu, Guanghui
    Zhu, Rongfei
    CYTOKINE, 2025, 185
  • [22] Treatment of Chronic Spontaneous Urticaria: a Focused Update in Omalizumab
    Blackwell, Whitney A.
    Khan, David A.
    CURRENT TREATMENT OPTIONS IN ALLERGY, 2019, 6 (03) : 175 - 188
  • [23] Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria
    Keskinkaya, Zeynep
    Kaya, Ozge
    Mermutlu, Selda Isik
    Ogretmen, Zerrin
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2024, 185 (08) : 786 - 793
  • [24] Omalizumab and treatment-resistant chronic spontaneous urticaria
    Akyol, Aynur
    Oktem, Ayse
    Akay, Bengu Nisa
    Kundakci, Nihal
    Boyvat, Ayse
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2015, 49 (03): : 180 - 183
  • [25] Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab
    Watanabe, Haruka
    Takahagi, Shunsuke
    Hayama, Koremasa
    Fukunaga, Atsushi
    Nakagawa, Yukinobu
    Inomata, Naoko
    Chinuki, Yuko
    Hide, Michihiro
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024,
  • [26] Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria
    Skander, D.
    Allenova, A.
    Maurer, M.
    Kolkhir, P.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 53 (02) : 91 - 93
  • [27] Safety and efficacy of omalizumab treatment in chronic spontaneous urticaria
    Tat, Tugba Songul
    CUKUROVA MEDICAL JOURNAL, 2018, 43 (04): : 903 - 907
  • [28] Treatment of Chronic Spontaneous Urticaria: a Focused Update in Omalizumab
    Whitney A. Blackwell
    David A. Khan
    Current Treatment Options in Allergy, 2019, 6 : 175 - 188
  • [29] Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
    Thomas B. Casale
    Ana Maria Gimenez-Arnau
    Jonathan A. Bernstein
    Michael Holden
    Torsten Zuberbier
    Marcus Maurer
    Dermatology and Therapy, 2023, 13 : 2573 - 2588
  • [30] Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
    Casale, Thomas B.
    Gimenez-Arnau, Ana Maria
    Bernstein, Jonathan A.
    Holden, Michael
    Zuberbier, Torsten
    Maurer, Marcus
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2573 - 2588